clotting factors

出典: meddic

血液凝固因子

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/11/18 15:54:02」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Combination peel with incorporated fractional prickle coral calcium for the treatment of keratosis pilaris: a pilot study.
  • Park KY1, Son IP, Choi SY, Seo SJ, Hong CK.Author information 1Departments of Dermatology, Chung-Ang University College of Medicine , Seoul , South Korea.AbstractBACKGROUND: Keratosis pilaris (KP) is a common condition of follicular plugging with variable erythema. There is a lack of reliable response to the treatment of KP.
  • The Journal of dermatological treatment.J Dermatolog Treat.2014 Aug;25(4):314-8. doi: 10.3109/09546634.2012.671914. Epub 2012 Apr 12.
  • BACKGROUND: Keratosis pilaris (KP) is a common condition of follicular plugging with variable erythema. There is a lack of reliable response to the treatment of KP.OBJECTIVE: We evaluated the effect and safety of combination peel with fractional prickle coral calcium (FCR™) in the treatment of KP.
  • PMID 22385102
  • Anticoagulant medication at time of needle biopsy for breast cancer in relation to risk of lymph node metastasis.
  • Ljung R1, Sennerstam R, Mattsson F, Auer G, Lagergren J.Author information 1Upper Gastrointestinal Surgery Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.AbstractAnticoagulant treatment might enhance the natural defense against tumor cell dissemination caused by diagnostic needle biopsy by counteracting thrombocyte coating of such cells. To clarify whether women using anticoagulant treatment at the time of biopsy have a lower occurrence of lymph node metastasis, we conducted a nationwide Swedish cohort study of 26,528 female incident breast cancer patients in 2006-2011. Point risk ratio (RR) of risk of lymph node metastasis among users of anticoagulant treatment adjusted for age, T-stage, socioeconomic factors, and concomitant medication was RR = 0.94, (95% CI: 0.87-1.03), and lower in younger women (RR = 0.80, 95% CI 0.50-1.29). Although nonsignificant, these associations may underestimate a true negative association since women using anticoagulant treatment are likely to have more concomitant diseases, lead an unhealthier lifestyle, and have lower participation in mammography screening. These findings provide some support for the hypothesis that anticoagulant medications might counteract breast cancer spread caused by needle biopsy.
  • International journal of cancer. Journal international du cancer.Int J Cancer.2014 Jul 1;135(1):238-41. doi: 10.1002/ijc.28671. Epub 2013 Dec 31.
  • Anticoagulant treatment might enhance the natural defense against tumor cell dissemination caused by diagnostic needle biopsy by counteracting thrombocyte coating of such cells. To clarify whether women using anticoagulant treatment at the time of biopsy have a lower occurrence of lymph node metasta
  • PMID 24346771
  • Genotype and phenotype report on patients with combined deficiency of factor V and factor VIII in Iran.
  • Karimi M1, Cairo A, Safarpour MM, Haghpanah S, Ekramzadeh M, Afrasiabi A, Shahriari M, Menegatti M.Author information 1aHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran bA. Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, University of Milan and Luigi Villa Foundation, Milan, Italy cShiraz University of Medical Sciences, Shiraz, Iran.AbstractCombined factor V (FV) and factor VIII (FVIII) deficiency is a rare autosomal recessive bleeding disorder characterized by mild-to-moderate bleeding. Epistaxis, postsurgical bleeding and menorrhagia are the most common symptoms. The aim of this study is to report the phenotype-genotype characterization carried out in patients affected with combined FV and FVIII deficiency from Iran. A cross-sectional study was conducted in Shiraz Hemophilia Center, southern Iran. Twelve cases, seven men and five women coming from eight families were included in our study after taking consent form. Coagulation activity for all patients was measured. All exons and intron-exon junctions of lectin mannose binding protein 1 (LMAN1) gene and multiple coagulation factor deficiency 2 genes were amplified by PCR, and subsequently sequenced by the Sanger method. Patients[Combining Acute Accent] age ranged from 6 to 59 years mean ± SD: 23.8 ± 15.4 years and median: 22 years. No patient presented with severe bleeding symptom. Only one patient had severe FV and FVIII deficiency (both factor levels <1%). Four different type of mutations (duplication, insertion, splice site and nonsense), occurring in different locuses, were identified on LMAN1 gene in 12 Iranian patients. There was a significant correlation between FV and FVIII levels, which is indicative of association with loss of function of LMAN1 gene, and reduced plasma levels of both factors. Our study showed that all of our characterized patients with combined FV and FVIII deficiency present different homozygous mutations on LMAN1 gene introducing a premature stop codon. Larger studies are needed to calculate the correlation between factor levels, genetic and bleeding symptoms.
  • Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.Blood Coagul Fibrinolysis.2014 Jun;25(4):360-3. doi: 10.1097/MBC.0000000000000046.
  • Combined factor V (FV) and factor VIII (FVIII) deficiency is a rare autosomal recessive bleeding disorder characterized by mild-to-moderate bleeding. Epistaxis, postsurgical bleeding and menorrhagia are the most common symptoms. The aim of this study is to report the phenotype-genotype characterizat
  • PMID 24389588

和文文献

  • Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation – Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging –
  • Silent Cerebral Ischemic Lesions After Catheter Ablation of Atrial Fibrillation in Patients on 5 Types of Periprocedural Oral Anticoagulation – Predictors of Diffusion-Weighted Imaging-Positive Lesions and Follow-up Magnetic Resonance Imaging –
  • The First Case of Deceased Donor Liver Transplantation for a Patient with End-Stage Liver Cirrhosis Due to Human Immunodeficiency Virus and Hepatitis C Virus Coinfection in Japan

関連リンク

Clotting factors Substances in the blood that act in sequence to stop bleeding by forming a clot. Mentioned in: Partial Thromboplastin Time coagulation factors; clotting factors approximately 20 soluble plasma factors, including ...
What are rare clotting factor deficiencies? Rare clotting factor deficiencies are a group of inherited bleeding disorders caused by a problem with one or several clotting factors. Clotting factors are proteins in the blood that control ...

関連画像

Clotting FactorsPinterest • The world’s catalog of Clotting+Factors.pngClotting factors and their synonyms Clotting factors mnemonicand the clotting factors are here


★リンクテーブル★
先読み血液凝固因子
関連記事factor」「clotting

血液凝固因子」

  [★]

coagulation factor (Z), clotting factor, blood coagulation factor, blood coagulation factors
ビタミンK



血液凝固因子

  • PT.261
名称 同義語 分子量

(kDa)

血漿中濃度

(μg/ml)

半減期

(day)

内因系のプロ酵素 XII Hageman因子 80 29 2
  プレカリクレイン Fletcher因子 88 45  
  XI PTA 160 4 2.5
ビタミンK依存 VII proconvertin 50 0.5 0.2
凝固プロ酵素 IX Christmas因子 57 4 1
  X Stuart因子 57 8 1.5
  II プロトロンビン 70 150 3
補助因子 III 組織因子   0  
  血小板ホスホリピド        
  高分子量キニノゲン   120 70  
  V proaccelerin 330 7 1.5
  VIII 抗血友病因子     0.5
フィブリン堆積因子 I フィブリノゲン 340 2500 4.5
  XIII フィブリン安定因子 320 8 7
抑制物質 アンチトロンビンIII   58 150 2.5
  • 標準血液病学 p.217
15種類ある
凝固因子 慣用語・同義語 ビタミンK依存 血液中半減期(hr) 産生器官 染色体座乗部位
I fibrinogen   100-150 肝臓 4q26
II prothronbin 50-80 肝臓 11p141-q12
III tissue thromboplastin     体の各組織 1pter-p21
IV calcium ion     肝臓  
V labile factor/proaccelerin   24 肝臓 1q21-q25
VII stable factor/proconvertin 6 肝臓 13q34
VIII antihemophilic factor   12 細網系? xq28
IX Christmas factor 24 肝臓 xq26.3-q27.2
X Stuart factor 25-60 肝臓 13q34
XI plasma thromboplastin antecedent   40-80 肝臓 4q35
XII Hageman factor   50-70 肝臓 5q33-qter
XIII fibrin stabilizing factor   150 肝臓 6p24-p21.3
prekallikrein Fletcher factor   35 肝臓 4q35
hight molecular weight kininogen Fitzgerold factor   150 肝臓 3q26-qter
von Willebrand factor     24 血管内皮

血小板 糸球体

12pter-p12


産生部位

  • ほとんどが肝臓
  • 例外:

臨床関連


-凝固因子


factor」

  [★]

  • n.
elementelementaryfactorialparameter

WordNet   license wordnet

「be a contributing factor; "make things factor into a company''s profitability"」

WordNet   license wordnet

「any of the numbers (or symbols) that form a product when multiplied together」

WordNet   license wordnet

「an independent variable in statistics」

WordNet   license wordnet

「anything that contributes causally to a result; "a number of factors determined the outcome"」

PrepTutorEJDIC   license prepejdic

「(…の)『要因』,(…を生み出す)要素《+『in』+『名』(do『ing』)》 / 囲数,約数 / 代理人,《おもに英》仲買人 / =factorize」

WordNet   license wordnet

「consider as relevant when making a decision; "You must factor in the recent developments"」
factor in, factor out

WordNet   license wordnet

「resolve into factors; "a quantum computer can factor the number 15"」
factor in, factor out


clotting」

  [★]

  • n.
clotcoagulatecoagulationsolidificationsolidifyhemostasis




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡